CONMED (NYSE: CNMD) posts investor presentation with preliminary 2026 outlook

Rhea-AI Filing Summary

CONMED Corporation is sharing an investor presentation as part of its appearance at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation, furnished as Exhibit 99.1, includes the company’s preliminary 2026 financial guidance and is available on its website in the Investors section under News & Events – Presentations.

The information in this report and the attached presentation is being furnished rather than filed under U.S. securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other filings unless specifically referenced.

false 0000816956 0000816956 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-39218		16-0977505
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

11311 Concept Blvd Largo, FL		33773
(Address of principal executive offices)		(Zip code)

(727) 392-6464

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		CNMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

CONMED Corporation (the “Company”) is furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation that the Company will be presenting at the J.P. Morgan Healthcare Conference on January 12, 2026. The investor presentation includes preliminary 2026 financial guidance and is available on the CONMED Corporation website www.conmed.com in the Investors section under News & Events-Presentations.

The information contained in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly provided by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is included as part of this Current Report on Form 8-K: 

Number		Description of Exhibits
99.1		CONMED Corporation Investor Presentation dated January 12, 2026.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:		January 12, 2026		CONMED CORPORATION
						(Registrant)
				By:		/s/ Todd W. Garner
				Name:		Todd W. Garner
				Title:		Executive Vice President, Finance and Chief Financial Officer

FAQ

What did CONMED (CNMD) disclose in its latest 8-K?

CONMED furnished an investor presentation as Exhibit 99.1, which it will present at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation includes preliminary 2026 financial guidance and is available on the company’s website in the Investors section.

Where can investors find CONMED’s preliminary 2026 financial guidance?

The preliminary 2026 financial guidance is included in CONMED’s investor presentation dated January 12, 2026. It can be accessed on www.conmed.com in the Investors section under News & Events – Presentations.

What event is CONMED presenting at with this investor presentation?

CONMED is using the investor presentation in connection with its appearance at the J.P. Morgan Healthcare Conference on January 12, 2026.

Is CONMED’s investor presentation considered filed with the SEC?

No. The report states that the information in the investor presentation and the related report is being furnished and not filed under the Securities Exchange Act of 1934 and the Securities Act of 1933, unless specifically incorporated by reference in another filing.

Who signed CONMED’s January 12, 2026 report?

The report was signed on behalf of CONMED Corporation by Todd W. Garner, who is the company’s Executive Vice President, Finance and Chief Financial Officer.

What exhibits are included with CONMED’s January 12, 2026 8-K?

The report includes Exhibit 99.1, the CONMED Corporation Investor Presentation dated January 12, 2026, and Exhibit 104, the cover page formatted in Inline XBRL.